Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial. / Egefjord, Lærke; Gejl, Michael; Møller, Peter Arne; Brændgaard, Hans; Gottrup, Hanne; Antropova, Olga; Møller, Niels; Poulsen, Henrik E; Gjedde, Albert; Brock, Birgitte; Rungby, Jørgen.
I: Danish Medical Bulletin (Online), Bind 59, Nr. 10, 10.2012, s. A4519.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial
AU - Egefjord, Lærke
AU - Gejl, Michael
AU - Møller, Peter Arne
AU - Brændgaard, Hans
AU - Gottrup, Hanne
AU - Antropova, Olga
AU - Møller, Niels
AU - Poulsen, Henrik E
AU - Gjedde, Albert
AU - Brock, Birgitte
AU - Rungby, Jørgen
PY - 2012/10
Y1 - 2012/10
N2 - Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-ß (Aß) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated in the pancreas. Premature cellular degeneration is seen in both diseases. Glucagon-like peptide-1 (GLP-1) reduces the amount of Aß and improves cognition in animal studies. The present study tests the hypothesis that treatment with the long-acting GLP-1 receptor agonist liraglutide affects the accumulation of Aß in patients with AD.
AB - Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-ß (Aß) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated in the pancreas. Premature cellular degeneration is seen in both diseases. Glucagon-like peptide-1 (GLP-1) reduces the amount of Aß and improves cognition in animal studies. The present study tests the hypothesis that treatment with the long-acting GLP-1 receptor agonist liraglutide affects the accumulation of Aß in patients with AD.
M3 - Journal article
C2 - 23158895
VL - 59
SP - A4519
JO - Danish Medical Journal
JF - Danish Medical Journal
SN - 2245-1919
IS - 10
ER -
ID: 44913415